MO50-7 Evaluation of preoperative chemotherapy and cancer genome therapy for intrahepatic cholangiocarcinoma in our hospital.

MLA

Matsumoto, T., et al. “MO50-7 Evaluation of Preoperative Chemotherapy and Cancer Genome Therapy for Intrahepatic Cholangiocarcinoma in Our Hospital.” Annals of Oncology, vol. 35, Oct. 2024, p. S1356. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.07.610.

APA

Matsumoto, T., Hayashi, H., Yumoto, S., Miyamoto, H., Adachi, Y., Kanemitsu, K., Tajiri, T., Ofuchi, T., Ogawa, D., Shiraishi, Y., Takematsu, T., Itoyama, R., Kitano, Y., Nakagawa, S., Mima, K., Okabe, H., Tanaka, Y., & Baba, H. (2024). MO50-7 Evaluation of preoperative chemotherapy and cancer genome therapy for intrahepatic cholangiocarcinoma in our hospital. Annals of Oncology, 35, S1356. https://doi.org/10.1016/j.annonc.2024.07.610

Chicago

Matsumoto, T., H. Hayashi, S. Yumoto, H. Miyamoto, Y. Adachi, K. Kanemitsu, T. Tajiri, et al. 2024. “MO50-7 Evaluation of Preoperative Chemotherapy and Cancer Genome Therapy for Intrahepatic Cholangiocarcinoma in Our Hospital.” Annals of Oncology 35 (October): S1356. doi:10.1016/j.annonc.2024.07.610.